Allena Pharmaceuticals (ALNA) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Allena Pharmaceuticals (NASDAQ: ALNA):

  • 11/27/2017 – Allena Pharmaceuticals is now covered by analysts at Wedbush. They set an “outperform” rating and a $30.00 price target on the stock.
  • 11/27/2017 – Allena Pharmaceuticals is now covered by analysts at Cowen Inc. They set an “outperform” rating on the stock.
  • 11/27/2017 – Allena Pharmaceuticals is now covered by analysts at Jefferies Group LLC. They set a “buy” rating and a $22.00 price target on the stock.
  • 11/27/2017 – Allena Pharmaceuticals is now covered by analysts at Credit Suisse Group AG. They set an “outperform” rating and a $22.00 price target on the stock.

Shares of Allena Pharmaceuticals Inc (NASDAQ ALNA) opened at $14.25 on Wednesday. Allena Pharmaceuticals Inc has a fifty-two week low of $8.66 and a fifty-two week high of $15.40.

In other news, Director James N. Topper bought 500,000 shares of Allena Pharmaceuticals stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $7,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of Allena Pharmaceuticals stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, with a total value of $504,000.00. The disclosure for this purchase can be found here.

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Receive News & Ratings for Allena Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply